Canaccord Genuity Reaffirms Buy Rating on BVS

Canaccord Genuity has reiterated its Buy rating on BVS, setting a price target of $15. This reaffirmation came on June 16, 2026, as analyst Caitlin Cronin expressed confidence in the company's prospects. BVS shares are currently trading at $8.60.

Other Institutional Activity in BVS

Several institutional investors have been active in BVS recently. Nantahala Capital Management increased its holdings by 75,000 shares, bringing its total to 6,122,403 shares valued at approximately $55.9 million. BlackRock, Inc. added 9,357 shares, ending with 3,133,541 shares worth about $28.6 million. Meanwhile, Royce & Associates LP made a more significant move, adding 290,000 shares to reach a total of 1,541,282 shares, valued around $14.1 million.

Insider Buying and Selling at Bioventus Inc.

On June 3, 2026, several insiders at BVS made notable purchases. Philip Cowdy, Mary Kay Ladone, Pat Beyer, Martin Sutter, and Guido Neels each bought 25,146 shares. William Hawkins also acquired 30,994 shares. These transactions were not part of any pre-arranged trading plans.

Analysts Set New Price Targets

On June 16, 2026, Canaccord Genuity maintained its Buy rating on BVS with a $15 price target. Previously, Barrington Research also maintained a Buy rating with a $14 target on May 22, 2026. Craig-Hallum kept its Buy rating with a $16 target on March 6, 2026. The consensus among analysts remains optimistic, with a strong Buy recommendation and a mean target price reflecting positive expectations for BVS.

Bottom Line

Canaccord Genuity's reaffirmation of its Buy rating and a $15 target demonstrates continued confidence in BVS's potential. Institutional investors have made various adjustments to their holdings, indicating active interest in the stock. Insider purchases further suggest confidence among company executives. As always, it's important for investors to remember that these analyses reflect past actions and may not indicate future performance.